ImmunoCellular Therapeutics (IMUC) 10-K2011 FY Annual report

Filed: 21 Mar 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: Accentia, add, Additionally, Adjunct, Affymax, ahead, AICPA, amex, Amgen, andten, Aptiv, ASU, automatically, Axella, began, Betty, Bill, binomial, Biopharma, Biovest, BioWa, bladder, boutique, bowel, carcinomain, cavity, CD, chance, Chicago, Chin, commonly, confined, conjunction, country, CPA, cryopreservation, customary, David, decision, dentritic, die, ductal, Elan, England, escape, EU, extracting, female, final, finalized, Fractor, Galena, Gamble, Genmedica, Gordon, Hakko, Helen, HemaCare, Ho, ICT, implantation, impoverished, incidence, inflammatory, Innovation, intrinsic, invasion, JHU, Kim, Kirin, KOSAN, Kyowa, Language, Lifetime, lymphoma, magna, matching, melanoma, Melinda, merchant, mesothelin, metabolic, minimum, MLV, Moore, mouse, neglected, NGM, nonprofit, Northwestern, NYSE, OneWorld, Onyx, overseen, Oxford, OXiGENE, passage, peritoneal, peritoneum, POTELLIGENT, preclude, Procter, Progenitor, Provenge, quick, randomized, regrow, reintroducing, repayment, repositioned, reproductive, resection, resold, restructured, revalued, root, Scholarship, shedding, solution, spontaneously, Squibb, storing, supply, synthetic, Thethird, toeight, turnover, twenty, UCSF, underwritten, UPENN, Verastem, vi, vii, viii, website, XBRL, Zevalin

Removed: Anatomy, art, Bertelsmann, cancelled, carryforward, Claremont, cleared, Client, comprising, conform, consolidated, constructive, contemplated, context, COSO, Cyanimid, CytRx, Daniel, decided, DigitalMed, faith, graduate, guidance, harassment, hedge, Immunomedica, improve, incorporate, India, interfere, interference, Laird, Leerink, Letter, manager, Martuza, mature, McKenna, Medarex, Mehta, Memorandum, methodology, Mosk, Nevada, NIH, nominee, Norton, ofNeurological, package, predecessor, pursuing, RAB, range, reclassified, recognition, register, rejected, relinquishment, relocated, Renshaw, resell, resignation, retaliation, ribonucleic, Robert, Rockefeller, Rodman, SBIR, SGN, sheet, Subscription, Suisse, Supplementary, Swann, taxable, Tenet, TherapyandMolecular, uncertainty, unlawful, unrealized, voluntarily, voluntary, Zevatin

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IMUC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to his knowledge:

The Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


	By:	/s/ Manish Singh, Ph.D.
Date: March 21, 2012		Name:	Manish Singh, Ph.D.
		Title:	President and Chief Executive Officer